
GHRH analog targeting visceral fat.
Tesamorelin is a synthetic GHRH analog with the strongest evidence of any peptide for reducing visceral adipose tissue (VAT) — the deep belly fat associated with metabolic risk.
Stimulates the pituitary to release GH in a physiological pattern, increasing IGF-1 and selectively reducing visceral fat over time.
Typical research protocol: 1–2 mg subcutaneously nightly. Often used in place of heavy CJC/Ipamorelin stacking.
For laboratory and research use only. Not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. All protocols are reference summaries provided for educational purposes — always consult a qualified healthcare professional.